News | Atrial Fibrillation | May 19, 2020

Heart Tissue Changes Can Predict Atrial Fibrillation Prior to Onset

PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling

PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell

May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the late-breaking PREDICT-AF trial showed first time there is extensive extracellular matrix (ECM) remodeling, which can be used as a new predictor for AF. The study was presented at the Heart Rhythm Society (HRS) 2020 Science virtual meeting.

The Tissue, Blood and Biomarkers to Predict Future Atrial Fibrillation (PREDICT-AF) study showed that extensive ECM remodeling, reaching beyond the deposition of collagens, takes place in the atria of patients long before they develop AF, said Joris R. de Groot, M.D., Ph.D., Amsterdam UMC, Amsterdam, Netherlands, who presented the results. He said the high accuracy of a gene panel to predict future AF may inspire further research to provide targets for diagnosis and primary prevention of AF.

The study included 150 patients (age 68±7 years, 87% men, 115 CABG, 11 valve surgery, 24 combined surgeries). Patients without a history of AF undergoing cardiothoracic surgery with a CHA2DS2-VASc score ≥2 were included and the left atrial appendage was excised (PREDICT-AF NCT03130985). Rhythm monitoring with multiple Holters was performed for 2 years. The primary endpoint was late-onset AF: any atrial tachyarrhythmia >30 sec, occurring >50 days after surgery. The expression of 25 genes related to structural or electrical remodeling was quantified with qPCR in all patients and associated with late-onset AF using Cox-regression analyses. Genes were selected based on a discovery phase (transcriptome sequencing of 22 atrial tissues). Gene panels were used to determine C-statistics.[1] 

Median follow-up was two years [1.5-2]. Post-operative AF occurred in 63 (42%) patients ≤50 days post-surgery and late-onset AF in 18 (12%). Gene expression of all 25 genes was similar in patients with and without post-operative AF <50 days. Patients with late-onset AF exhibited numerical down regulation of KCNJ2 and up regulation of SCN2B. There was a marked increased expression of extracellular matrix (ECM) genes encoding collagens and matricellular proteins that act as structural proteins and fibrogenic mediators. We found a strong correlation between ECM genes and the fibroblast activator Endothelin-1. 

The fraction of Vimentin positive cells (i.e. fibroblasts) was similar, suggesting fibroblast activation rather than proliferation. A gene panel including KCNJ2, COL8A2, and COL1A1 better discriminated late-onset AF (AUC=0.82) than a model with the most relevant clinical parameters (age≥75, LAVI and sex; AUC=0.69).

Find links to all the Heart Rhythm Society 2020 Late-Breaking Clinical Trials in Electrophysiology

Reference:

1. PREventive Left Atrial appenDage Resection for the predICtion of fuTure Atrial Fibrillation: Design of the PREDICT AF Study. J Cardiovasc Med (Hagerstown). 2019 Nov;20(11):752-761. doi: 10.2459/JCM.0000000000000868.

 

Related Content

Ablation and Biventricular Pacing Boosts Survival in Selected Atrial Fibrillation Patients in APAF-CRT Trial. #ESC #ESCcongress
News | Atrial Fibrillation | September 13, 2021
September 13, 2021 — Ablation plus cardiac resynchronization therapy (CRT) is superior to pharmacological rate contro
The Medtronic Linq II implantable cardiac monitor.

The Medtronic Linq II implantable cardiac monitor.

News | Atrial Fibrillation | September 08, 2021
September 8, 2021 — Continuous heart rhythm monitoring – with...
The Adagio Medical iCLAS cryoablation system is commercial in Europe and is also part of an ongoing FDA IDE trial in the U.S. #HRS21
News | Atrial Fibrillation | August 09, 2021
August 9, 2021 — Adagio Medical Inc., a provider of catheter ablation technologies for...
Rhythm Therapeutics gene, stem cell, therapy for atrial fibrillation.
News | Atrial Fibrillation | April 19, 2021
April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm Therape
Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

News | Atrial Fibrillation | January 29, 2021
January 29, 2021 — The U.S.
Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Feature | Atrial Fibrillation | January 27, 2021 | By John D. Day, M.D., T. Jared Bunch, M.D., and Matthew D. LaPlante
In our most challenging and distressing days, it is nice to think about a post-COVID-19 world. 
ECG with paroxysm correct form of atrial flutter. Getty Images

ECG with paroxysm correct form of atrial flutter. Getty Images

News | Atrial Fibrillation | December 23, 2020
December 23, 2020 — The American College of Cardiology (ACC) and the American Heart Association (AHA) has made two up